There’s no reason to discount the Bitcoin bull run yet, longer-term price data shows, but faith in an end-of-year rebound is thin.

Bitcoin, BTC PriceRead More

You might also be interested in reading Sandoz launches biosimilar Pyzchiva in U.S. for all approved Stelara indications.